The Efficacy of Low-Dose Enoxaparin in Psoriasis

Psoriasis is a frequently encountered inflammatory skin disease with unclear etiology and no curative therapy. Enoxaparin is a low-molecular weight heparin analogue. Heparin and its analogues in low doses have antiproliferative and immunomodulatory effects. Low-dose enoxaparin has inhibitory effects on T cell-mediated immune reactions. T lymphocytes play a key role in the immunpathogenesis of psoriasis. The aim of this study was to evaluate the efficacy of low-dose enoxaparin in the treatment of psoriasis. Twenty-three patients with chronic plaque and guttate psoriasis were enrolled in an open study. Patients were given subcutaneous injections of 5 mg enoxaparin once weekly for a total of 6 weeks. There was a statistically significant difference between the PASI (Psoriasis Area and Severity Index) scores at the beginning and at the 6th week follow up (p=0.008). Four out of 23 patients (17%) showed marked improvement (≥50% reduction in the PASI score), eight patients (35%) showed moderate improvement (25-49% reduction), five (22%) were unchanged (

PDF

___

1. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-10.
2. Prinz JC. Psoriasis vulgaris - a sterile antibacterial reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-32.
3. Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26: 362-7.
4. Lider O, Baharav E, Mekori YA, et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83: 752-6.
5. Lider O, Mekori YA, Miller T, et al. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990; 20: 493-9.
6. Cahalon L, Lider O, Schor H, et al. Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents. Int Immunol 1997; 9: 1517-22.
7. Pillai S, Gilliam L, Conrad HE, et al. Heparin and its non-anticoagulant analogues inhibit human keratinocyte growth without inducing differentiation. J Invest Dermatol 1994; 103: 647-50.
8. Hodak E, Yosipovitch G, David M, et al. Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J Am Acad Dermatol 1998; 38: 564-8.
9. Stefanidou MP, Ioannidou DJ, Panayiotides JG, et al. Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus. Br J Dermatol 1999; 141: 1040-5.
10. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
11. Prinz JC, Gross B, Vollmer S, et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 1994; 24: 593-8.
12. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, et al. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 1995; 95: 317-27.
13. Naparstek Y, Cohen IR, Fuks Z, et al. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 1984; 310: 241-4.
14. Fridman R, Lider O, Naparstek Y, et al. Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J Cell Physiol 1987; 130: 85-92.
15. Savion N, Vlodavsky I, Fuks Z. Interaction of T lymphocytes and macrophages with cultured vascular endothelial cells: attachment, invasion, and subsequent degradation of the subendothelial extracellular matrix. J Cell Physiol 1984; 118: 169-78.
16. Lider O, Cahalon L, Gilat D, et al. A disaccharide that inhibits tumor necrosis factor alpha is formed from the extracellular matrix by the enzyme heparanase. Proc Natl Acad Sci U S A 1995; 92: 5037-41.
17. Ingber A, Trattner A, Cohen IR, et al. Low doses of low molecular weight heparin in vivo inhibits the elicitation of contact hypersensitivity. Acta Derm Venereol 1994; 74: 454-6.
18. Patel RP, Shastri MD, Ming LC, et al. Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports. Front Pharmacol 2018; 9: 586.
19. Pacheco H, Kerdel F. Successful treatment of lichen planus with low-molecular-weight heparin: a case series of seven patients. J Dermatolog Treat 2001; 12: 123-6.
20. Akdeniz S, Harman M, Atmaca S, et al. The management of lichen planus with low-molecular-weight heparin (enoxaparin). Int J Clin Pract 2005; 59: 1268-71.
21. Ameen WA, Alphadhily ZS. Treatment of recaltritrant lichen planus with low molecular weight heparin (Enoxaparin). Med J Babylon 2011; 8: 93-103.
22. Yasar S, Serdar ZA, Goktay F, et al. The successful treatment of palmoplantar hyperkeratotic lichen planus with enoxaparin. Indian J Dermatol Venereol Leprol 2011; 77: 64-6.
23. Iraji F, Asilian A, Saeidi A, et al. Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial. Adv Biomed Res 2013; 2: 76.
24. Porter SR, Kirby A, Olsen I, et al. Immunologic aspects of dermal and oral lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83: 358-66.
25. Craven NM, Jackson CW, Kirby B, et al. Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001; 144: 849-53.
26. Piepkorn M, Pittelkow MR, Cook PW. Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol 1998; 111: 715-21.